Bentyl (Dicyclomine) and QT Prolongation
Bentyl (dicyclomine) is not known to prolong the QT interval and is not listed among medications that cause QT prolongation. Based on the available evidence, dicyclomine can be considered safe from a cardiac arrhythmia perspective.
Evidence Analysis
The 2023 Canadian Cardiovascular Society guidelines provide comprehensive lists of QT-prolonging medications, categorizing them by drug class 1. These guidelines emphasize the "anti's" - antibiotics (macrolides and fluoroquinolones), antifungals, antiarrhythmics, antipsychotics/antidepressants, antiemetics, and analgesics (including methadone and triptans). Dicyclomine, an anticholinergic antispasmodic, is notably absent from these comprehensive lists.
The FDA drug label for dicyclomine 2 describes its mechanism as an anticholinergic/antimuscarinic agent with direct smooth muscle effects. The label details common anticholinergic side effects (dry mouth, dizziness, blurred vision) but makes no mention of QT prolongation or cardiac arrhythmia risk. This is significant because medications with known QT-prolonging potential carry specific warnings in their FDA labeling.
Clinical Context
The guidelines recommend checking www.crediblemeds.org before prescribing medications with potential QT effects 1. This authoritative database does not list dicyclomine as a QT-prolonging agent. In contrast, the guidelines specifically mention hydroxychloroquine and azithromycin as "definite causes of torsade de pointes" 3, demonstrating that when drugs do carry this risk, it is clearly documented.
Research on drug-induced QT prolongation 4, 5, 6 identifies multiple medication classes associated with this risk, but anticholinergic antispasmodics like dicyclomine are not among them. The multicenter study examining drug-induced QTc prolongation in everyday practice 5 found associations with clarithromycin, haloperidol, furosemide, and glyceryl trinitrate, but not with anticholinergic agents.
Important Caveats
While dicyclomine itself does not prolong QT:
- Avoid combining with known QT-prolonging drugs when possible, as the guidelines emphasize that multiple QT-prolonging medications increase risk 1
- Monitor electrolytes in patients taking dicyclomine with diuretics, as hypokalemia and hypomagnesemia can independently prolong QT 1
- Consider baseline ECG only if the patient has other risk factors: female gender, elderly age, structural heart disease, electrolyte abnormalities, or concurrent use of other QT-prolonging medications 1
Bottom Line
Dicyclomine can be prescribed without specific concern for QT prolongation. Routine ECG monitoring is not indicated solely for dicyclomine use. Focus instead on the drug's documented anticholinergic side effects and contraindications in patients with glaucoma, obstructive uropathy, or severe ulcerative colitis 2.